spacer
home > epc
PUBLICATIONS

European Pharmaceutical Contractor

 

European Pharmaceutical Contractor (EPC) is designed to fill a unique position in pharmaceutical publishing. Providing a dedicated platform of communication and information for the international pharmaceutical contract market, it consists of a series of articles and case studies written by eminent figures in contractor groups and traditional multinational pharmaceutical companies.

Each quarterly edition examines areas of importance – both economic and technical – to contract research organisations, contract manufacturers, regulatory controllers, consultants and analysts. This enables regulatory bodies to link directly with policy-makers both in major contractor groups and pharmaceutical companies, and thereby convey regulatory information directly from the governing bodies, but also ensure debate between the policy-makers and consultancy groups.

 

For further information please contact:

Advertising
Dean Dalton

Editorial
Aimee-Rose O'Driscoll

We're also on Twitter! Follow us @EPCmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.


View the digital version of EPC




 

epc
 
 
Featured in this issue
Interview
Industry Interview

Maximum Protection


Neil Coulson at Baker Botts discusses the recent difficulties and developments in the intellectual property field, and advises on how pharma can maintain value.

Research and Development
Diseases of Ageing

Finding the Trigger


Ciriaco Maraschiello at Harlan Contract Research Services believes that, in order to produce more efficacious treatments for age-related conditions, the triggering mechanisms of these diseases need to be fully understood.

  Review
In Conclusion

Breaking News


Graham Hughes
reviews pharma's recent news items, and suggests that the industry is receiving selective press attention.

spacer
Edited by
Dr Graham Hughes,
Consultant in
Pharmaceutical
Development
Published quarterly in
March, June,
September and December

Banner of Samedan app.EPC on Samedan
 
Industry Events

Advances and Progress in Drug Design

16-17 February 2015, Marriott Regents Park Hotel, London, UK

SMi are proud to present the 14th annual conference, Advances and Progress in Drug Design, taking place on 16th & 17th February 2015 in Central London.  Join us as we ask questions such as: What are the key challenges in biotherapeutics discovery? How have computational and predictive tools matured for the application of drug discovery? Are there novel ways to inhibit kinase targets? How can we successfully apply ligand-based and structure based computational approaches for the rational design of novel GPCR antagonists? What are the best approaches in building a robust technology pipeline for robust fragment based drug discovery?
More info >>

 
News and Press Releases

Scope International’s Use of ArisGlobal’s Clinical Data Management Platform Proves the Value of a Unified Solution

STAMFORD, CT—  5 November, 2014 —  Scope International AG, a global, full-service contract research organization (CRO) is reaffirming its three-year relationship with ArisGlobal with two additional studies in its use of the Total Clinical™ Data Management (TCDM) cloud-based platform for unified clinical data management.  Scope International is currently using the TCDM platform for electronic data capture (EDC), electronic patient reported outcomes (ePRO), and randomization as well as trial supply management (RTSM) in a double-blind, randomized study that spans 36 countries with more than 180 active sites.
More info >>

air transport logo

 

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement